免费网络研讨会：氯胺酮监管与治疗性迷幻药物的未来

未来几年，美国食品药品监督管理局（FDA）很可能批准含有裸盖菇素和MDMA的药物制剂。尽管关于裸盖菇素和MDMA药物疗法的监管方式仍存在诸多未知，但我们认为，过去几年在氯胺酮疗法中观察到的许多趋势同样适用于这些新型药物疗法。

To that end, Harris Sliwoski attorneys recorded a free webinar on Tuesday, April 11 @ 10:00am PT in which they addressed the current regulatory landscape for ketamine, some potential bigger regulatory changes on the horizon, as well as some of the key issues for future FDA-approved psychedelic drug therapies.

在此之前，更多信息可参见我们的迷幻剂专题页面。